aniws. £E~et«,2*%%,ssan.¢3Va<.1»:»i' mat». ‘%‘:,aiTaa.w'*»
`
`
`
`menu:
`
`%fin Login | Register | Subscription
`
`OTC Guide | Cou-Co
`
`TLI6-1311323
`W HEART FAILURE
`U) wovmms
`;,
`K
`I'|lI'\Et.'-4uv1f.Il'll|.’l.|'.'5
`
`I
`
`;
`
`El 331-! H:In.'arl:|s
`
`12-'1-1
`
`HEART FAILURE
`SHATTER5
`
`LEARN I-IIJRE HERE )
`
`'E.".'.i'
`
`¢.«.'”.r.
`
`(T) N QVA RT I 5
`I'JllUKl1.\lIl‘l|l..‘I|'\
`
`.3.-.1
`
`Video Resources
`'I1I:—:I'I[
`
`‘_-‘IE-2:1?
`
`Lupin Pharmaceuticals, Inc.
`
`Published Online: Monday, July 14, 2014
`
`Follow Pharmacy_Times:
`
`*
`
`*
`
`i rrrrLil,
`”'
`Lfifl
`
`‘
`
`.§.LUP|N
`
`'5'
`
`PHARMACEUTICALS INC.
`
`Research Driven. Quality Committed. Customer Focused.
`
`Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. (“Lupin”) is dedicated to delivering high-
`
`quality branded and generic pharmaceutical products trusted by health care professionals and patients
`
`across the United States. Lupin is the exclusive US distributor for all of the products developed and
`
`manufactured by its parent company, Lupin Ltd., and other affiliate companies. Lupin remains the fifth-
`
`largest generic player in the United States by prescriptions, growing at a rate of 9.9% year over year, the
`
`fastest among the top 5 manufacturers (IMS Health, National Prescription Audit, September 2013).
`
`http://www.pharmacytimes.com/publications/su...
`
`7/1/2015
`
`2:42:57 PM
`
`Janssen Ex. 2008
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`lPR2015-01030
`
`(Page 1 of 4)
`
`

`
`SHATTERS
`
`Relate‘ Articles
`
` HEART FAILURE
`
`For many pharmacy organiza ions, the Supreme
`Court King v. Burwell decisiti yphp{girqg.atI‘|Q'f | 5
`Affordable Ca re Act's tax subsidiesfeunded Gflr .a..
`'\
`potential confusion for patients concerning health
`in$'u1r.éfide'_.:'L
`I Lib 'I'_.'1'_-"u
`
`Generic Product News (June 2015)
`Read about the new generic products featured in
`June.
`
`Ruling for Drug Maker Could Impact Generics
`Industry
`The Office of the Assistant Secretary for Planning
`and Evaluation released an analysis on the efforts of
`pharmaceutical companies to thwart generic
`competition as the market exclusivity period of one
`of its brand name drugs nears expiration.
`
`4 Generic Versions of lntuniv ADHD Drug
`Launched in US
`
`Four separate drug manufacturers have launched
`generic versions of Shire’s lntuniv ADHD treatment
`for children aged 6 to 17 years.
`
`MORE ARTICLES >>
`
`Lupin’s journey over the past decade has been very exciting. The birth of Lupin began in 2003 with 3
`
`Baltimore-based employees and Lupin’s first US generic product approval. Lupin now markets 71 products,
`
`generating over $800 million in net revenues. Lupin has grown in scale, breadth, and depth. In April 2014,
`
`Lupin became the largest tenant in the Harborplace Tower office building, located in Ba|timore’s vibrant
`
`Inner Harbor. The Lupin name is now prominently displayed on its headquarters office building. Lupin has
`
`brought significant, high-quality, affordable medicines to the market, which has helped fuel the growth of its
`
`business. V\fith a robust pipeline in hand, along with continued investments, expansion of technologic
`
`capabilities, and an aspiration to grow the business through organic efforts and acquisitions, Lupin isjust
`
`getting started.
`
`RECENT GENERIC
`
`BRAND EQUIVALENT
`
`LAUNCHES
`
`Eszra-pi-zlcrnte Tablets
`Doxycycliine Capsules USP
`_
`Zolpidern Tartrate ER
`Tablfit-5 U5"
`Rifalbutin Capsules USP‘
`_
`_
`Nla-I‘Ill'I ER Tablets USP
`
`Lunestafl
`Monodax“
`_
`Ambienfi‘ CR
`
`Mynzobutinfl
`_
`NIaspan®
`
`The momentum of Lupin’s
`
`sustained growth year over
`
`year is a result of a
`
`valuable pipeline, solid
`Customer relationships,
`am flawless eXe°”“°“-
`Lupin has 94 ANDAs
`pending FDA approval (as
`of May 2014), and
`l”"°d”°ed 19 9e”e”°
`products last fiscal year
`(Fy)_ Lupinas products are
`generally vertically
`
`integrated, which ensures quality control throughout each step of product development and manufacturing.
`
`This gives Lupin an unparalleled advantage over its competitors, as Lupin is able to control its supply chain,
`
`as well as offer competitive pricing.
`
`R&D
`
`Lupin recognizes the importance of R&D, and globally invested more than 8% of its FY 2013 net sales in
`
`this area. In FY 2014, the US generics business reported upward growth of 32%, with revenues of $723
`
`million, up from $548 million in FY 2013. New launches contributed 18% of the US generics revenue. Key
`
`launches included Duloxetine HCI DR Capsules, Abacavir Lamivudine Zidovudine Tablets, Gatifloxacin
`
`Ophthalmic Solution, and Niacin ER Tablets.
`
`Lupin is seeking to expand its portfolio to offer products in new therapeutic areas, including dermatology
`
`and inhalation. Lupin’s affiliate company, Lupin |nc., recently announced the start-up of its first Research &
`
`Development facility, located in Coral Springs, Florida. This R&D site will be a 30,000 sq ft state-of-the-art
`
`http ://www.pharmacytimes. com/pub1ications/su. .
`
`.
`
`7/1/2015
`
`2:42:57 PM
`
`Janssen Ex. 2008
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`IPR2015-01030
`
`(Page 2 of 4)
`
`

`
`facility and will be focusing on the development of branded and generic oral and nasal inhalation products.
`
`Lupin remains committed to investing in the development of new branded and generic products in multiple
`
`therapeutic areas and dosage forms.
`
`Quality & Supply Chain
`
`Lupin’s commitment to quality is unquestionable. Lupin has earned its reputation for reliability by
`
`consistently delivering high-quality products. Lupin has a strong corporate culture of excellence in place,
`
`ensuring strict adherence to FDA regulations year after year.
`
`Lupin’s global affiliates continue to expand their manufacturing capabilities by adding state-of-the art
`
`facilities. This enables Lupin to continue to exceed customer demands and strengthen its overall supply
`
`chain by creating efficiencies that ensure cutting-edge response time and continuous product supply.
`
`The Lupin Advantage
`
`“Over the last decade, Lupin has successfully ring-fenced its business by creating competitive advantages
`
`which have become distinctive differentiators. We have done that by calibrating our choice of markets; entry
`
`into new geographies, new therapies, the business and product mix; not to mention a rigorous attention to
`
`input costs in a never-ending quest for better efficiencies.” — Dr. Kamal K. Sharma, managing director,
`
`Lupin Ltd.
`
`For more information, visit wvvw.lupinpharmaceuticals.com.
`
`
`W HEART FAILURE
`U) NOVARTIS
`‘
`‘
`V
`l‘l*lA|1MI|.CEl|l|C.I.|S
`
`l
`
`:
`
`El 331-! N:In.'arl:E.
`
`131 -1
`
`T-LE5-13] 12323
`
`Latest Issues
`
`........... . mwran
`
`Tim '
`"
`I 1*!-10-‘!
`='I=FI
`£1 ........my- aunt: 1
`Erfiiflé
`aL_u_v.Ir.~
`“
`**
`E,
`
`http://www.pharmacytimes.com/publications/su...
`
`7/1/2015
`
`2:42:57 PM
`
`Janssen Ex. 2008
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`lPR2015-01030
`
`(Page 3 of 4)
`
`

`
`Intellissphere, LLC. All Rights Reserved.
`
`Intellisphere, LLC
`666 Plainsboro Road
`Building 300
`Plainsboro, NJ 08536
`P: 609-716-7777
`F: 609-257-0701
`
`Copyright PharmacyTimes 2006-2015
`
`|\/IJH Associates
`American Journal of Managed Care
`Cure
`it/ID Magazine
`ONCLive
`OTCGLiide
`Specialty Pharmacy Times
`Targeted Oncology
`
`About Us
`Careers
`Contact Us
`Feedback
`Advertise
`Terms 3. Conditions
`Privacy
`Press Room
`
`http ://www.pharmacytimes. com/pub1ications/su. .
`
`.
`
`7/1/2015
`
`2:42:57 PM
`
`Janssen Ex. 2008
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 4 of 4)